S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
NASDAQ:KZIA

Kazia Therapeutics - KZIA Stock Forecast, Price & News

$1.00
-0.01 (-0.99%)
(As of 01/27/2023 08:55 PM ET)
Add
Compare
Today's Range
$0.97
$1.04
50-Day Range
$0.50
$1.05
52-Week Range
$0.50
$8.61
Volume
32,100 shs
Average Volume
104,019 shs
Market Capitalization
$13.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Kazia Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.25mentions of Kazia Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.05) to ($1.01) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.87 out of 5 stars

Medical Sector

1045th out of 1,049 stocks

Pharmaceutical Preparations Industry

510th out of 514 stocks


KZIA stock logo

About Kazia Therapeutics (NASDAQ:KZIA) Stock

Kazia Therapeutics Ltd. is a clinical stage oncology company It engages in the pharmaceutical research and development business. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Receive KZIA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KZIA Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Kazia Therapeutics CEO talks $4.5 million capital raise
KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
Kazia Therapeutics talks positive pre-clinical data for EVT801
Kazia Therapeutics provides cash outlook
Kazia Therapeutics Ltd (KZA)
Kazia Therapeutics Ltd
See More Headlines
Receive KZIA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KZIA Company Calendar

Today
1/30/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KZIA
Employees
2,021
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$11.35 million
Book Value
$0.97 per share

Miscellaneous

Free Float
13,737,000
Market Cap
$13.88 million
Optionable
Not Optionable
Beta
2.11

Key Executives

  • James Stuart Garner
    Chief Executive Officer, MD & Executive Director
  • Karen R. Krumeich
    Chief Financial Officer
  • John E. Friend
    Chief Medical Officer
  • Catherine Hill
    Secretary













KZIA Stock - Frequently Asked Questions

Should I buy or sell Kazia Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kazia Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" KZIA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KZIA, but not buy additional shares or sell existing shares.
View KZIA analyst ratings
or view top-rated stocks.

How have KZIA shares performed in 2023?

Kazia Therapeutics' stock was trading at $0.6149 at the beginning of the year. Since then, KZIA stock has increased by 62.6% and is now trading at $1.00.
View the best growth stocks for 2023 here
.

Are investors shorting Kazia Therapeutics?

Kazia Therapeutics saw a increase in short interest in January. As of January 15th, there was short interest totaling 247,100 shares, an increase of 64.2% from the December 31st total of 150,500 shares. Based on an average daily volume of 350,200 shares, the days-to-cover ratio is currently 0.7 days.
View Kazia Therapeutics' Short Interest
.

What other stocks do shareholders of Kazia Therapeutics own?
What is Kazia Therapeutics' stock symbol?

Kazia Therapeutics trades on the NASDAQ under the ticker symbol "KZIA."

How do I buy shares of Kazia Therapeutics?

Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kazia Therapeutics' stock price today?

One share of KZIA stock can currently be purchased for approximately $1.00.

How much money does Kazia Therapeutics make?

Kazia Therapeutics (NASDAQ:KZIA) has a market capitalization of $13.88 million and generates $11.35 million in revenue each year.

How many employees does Kazia Therapeutics have?

The company employs 2,021 workers across the globe.

How can I contact Kazia Therapeutics?

Kazia Therapeutics' mailing address is Three International Towers Level 24 300 Barangaroo Avenue, Sydney C3, 2000. The official website for the company is www.kaziatherapeutics.com. The company can be reached via phone at (129) 472-4101, via email at investment.consultant@novogen.com, or via fax at 61-2-9476-0388.

This page (NASDAQ:KZIA) was last updated on 1/30/2023 by MarketBeat.com Staff